| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| dinoprostone | prostaglandin d2 receptor 2 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | agonist |
| dinoprostone | prostaglandin e2 receptor ep1 subtype | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.72 | approved | agonist |
| dinoprostone | prostaglandin e2 receptor ep2 subtype | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.5 | approved | agonist |
| dinoprostone | prostaglandin e2 receptor ep2 | NA | Successful target | TTD , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.5 | approved | agonist |
| dinoprostone | prostaglandin e2 receptor ep2 | NA | Successful target | TTD , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.5 | approved | unknown |
| dinoprostone | prostaglandin e2 receptor ep3 subtype | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.06 | approved | agonist |
| dinoprostone | prostaglandin e2 receptor ep4 subtype | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
2.72 | approved | agonist |
| dinoprostone | prostaglandin f2-alpha receptor | NA | Successful target | TTD , DGIDB | Disease Management[MeSHID:D019468] Cervical Ripening[MeSHID:D020070] Postpartum Hemorrhage[MeSHID:D006473] Cessation of life[MeSHID:D003643] Pregnancy[MeSHID:D011247] Missed abortion[MeSHID:D000030] Gestational Trophoblastic Neoplasms[MeSHID:D031901] Uterus[MeSHID:D014599] Menstruation[MeSHID:D008598] Gestational Age[MeSHID:D005865] Hydatidiform Mole[MeSHID:D006828] Term Birth[MeSHID:D047929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.58 | approved | unknown |
| click here to return to the previous page | ||||||||